| DLR |
Report |
Core FFO per share (Q2 2026) |
BEAT |
pred ~$2.00 vs. cons $1.98 |
MEDIUM |
| DLR |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$1.68B vs. cons $1.66B |
MEDIUM |
| DLR |
Report |
Adjusted EBITDA (Q2 2026) |
IN-LINE |
pred ~$930M vs. cons $935M |
LOW |
| DLR |
Guide |
FY2026 Core FFO/share guidance |
BETTER |
guide ~$8.05-$8.15 vs. cons $8.05 (FY2026) |
MEDIUM |
| DLR |
Guide |
FY2026 Revenue guidance |
BETTER |
guide ~$6.70B-$6.85B vs. cons $6.70B (FY2026, incl. Teraco/Columbia consolidation) |
MEDIUM |
| DLR |
Guide |
Same-capital cash NOI growth (constant currency) guidance |
UNCHANGED |
guide ~4.0%-5.0% vs. cons ~4.5% (FY2026) |
MEDIUM |
| DLR |
Guide |
Net debt/Adjusted EBITDA leverage outlook |
LOWER |
guide ~5.2x-5.5x pro forma vs. prior trajectory of ~4.5x-4.7x (post Blackstone NoVA/Teraco/Columbia deals, YE2026) |
MEDIUM |
| DLR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
LOW |
| DLR |
Return |
5-day cumulative residual |
-0.5% (FADE) |
A likely headline beat on Core FFO/revenue and a reaffirmed-to-modestly-raised FY26 guide should drive an initial relief pop given the stock's 14% drawdown into the print, but the quarter's heavy debt+equity-funded M&A (Blackstone NoVA, Teraco, Columbia, Kansas City land) raises share count and pushes leverage back up from the 4.7x multiyear low just as accretion from these deals is explicitly framed as a 2027-2028 story, not 2026. Analysts are likely to trim near-term per-share accretion/leverage assumptions even after a beat (implicit out-period cut), causing the initial pop to fade over the following days as the dilution/leverage math gets digested on desks and in updated models. |
LOW |